Melatonin: a hepatoprotective agent against radioiodine toxicity in rats

Barlas, Afşar; Sadic, Murat; Atilgan, Hasan Ikbal; Bağ, Yusuf Murat; Onalan, Ali Kemal; Yumuşak, Nihat; Şeneş, Mehmet; Fidanci, Vildan; Pekcici, Mevlüt Recep; Korkmaz, Murat; Kısmet, Kemal; Koca, Gökhan

doi:10.4149/bll_2017_020

Cited by 12 publications

(7 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Rats treated under hypoxic conditions were widely used to investigate hypoxia‐induced oxidative stress in the liver, and AOPP levels in hypoxia‐treated rats could be used to evaluate protein oxidation and inflammation . In 2017, Barlas et al found that liver tissue AOPP levels were elevated in rats with radioiodine toxicity; it was determined that melatonin treatment could significantly decrease the AOPP levels compared to the radioiodine group. Moreover, Souza et al demonstrated that Pseudomonas aeruginosa infection increased the liver levels of AOPPs in experimentally infected silver catfish.…”

Section: Data Sourcesmentioning

confidence: 99%

Advanced oxidation protein products play critical roles in liver diseases

Zhao

Zhang

Ouyang

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

There is a complex oxidant and antioxidant system that maintains the redox homoeostasis in the liver. While suffering from exogenous or endogenous risk factors, the balance between oxidants and antioxidants is disturbed and excessive reactive oxygen species are generated, resulting in oxidative stress. Oxidative stress is prevalent in various liver diseases and is thought to be involved in their pathophysiology. Advanced oxidation protein products are generated under conditions of oxidative damage and are newly described protein markers of oxidative stress. Previous studies have underscored the universal pathogenic roles of oxidation protein products in various diseases. However, investigations into how these products participate in the development of liver diseases have been superficial and insufficient. In this review, we highlight the current understanding of the roles of advanced oxidation protein products in liver disease pathogenesis and the underlying mechanisms. Moreover, we summarize the current studies on advanced oxidation protein products in infectious and noninfectious, acute and chronic liver diseases. Different strategies for targeting these advanced oxidation protein products and future perspectives, which may pave the way for developing new therapeutic strategies, will also be discussed here.

show abstract

Section: Data Sourcesmentioning

confidence: 99%

Advanced oxidation protein products play critical roles in liver diseases

Zhao

Zhang

Ouyang

et al. 2019

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Renewed attention has been given to the role of melatonin in modulating behavior, immune system, and responses to stress, cancer and aging (2). Also, it has been proved that melatonin had anti-infl ammatory and antioxidant action (3). Preclinical studies have also shown that melatonin prevented short-and long-term memory impairments induced by chronic sleep deprivation and exhibited antidepressant-like actions (4,5).…”

Section: Introductionmentioning

confidence: 99%

Melatonin modulate the expression of α1- and β2-adrenoceptors in the hippocampus of rats subjected to unpredictable chronic mild stress

Stefanović¹,

Spasojević²,

Jovanović³

et al. 2018

BLL

View full text Add to dashboard Cite

show abstract

“…A rat model treated with intraperitoneal dexmedetomidine for preventing RAI-induced early liver damage observed that the rats treated with dexmedetomidine had lower mean scores of histopathologic parameters and lower malondialdehyde levels and higher total sulfhydryl and catalase activities than the RAI group [9]. Similarly, intraperitoneal melatonin treatment decreased the tissue advanced the oxidation of protein products and malondialdehyde levels and increase the total sulfhydryl level as well as reducing the early histopathologic damage of the liver after RAIT [34]. Moreover, montelukast had a partial radioprotector effect against the long-term liver damage at the third month of RAIT, particularly in terms of hyperemia and capsule thickening [10].…”

Section: Discussionmentioning

confidence: 99%

Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats

Kuşkonmaz¹,

Demirel

Koca

et al. 2021

Nuclear Medicine Communications

View full text Add to dashboard Cite

Objective The present study was aimed to explore the potential ameliorating effects of N-acetyl cysteine (NAC) against radioiodine (RAI)-induced early liver damage. Methods Thirty Wistar Albino male rats were arbitrarily allocated into three groups each containing 10 rats: the control group (group 1); the RAI group (group 2), oral 111 MBq/kg radioiodine was administered to rats; the RAI + NAC group (group 3), 150 mg/kg/day intraperitoneal NAC treatment was initiated 3 days prior to the RAI administration and continued for 10 days. Liver samples were obtained 24 h after the last dose of NAC therapy for biochemical and histopathologic evaluation. Results In the RAI + NAC group, the histopathologic damage was found significantly less than in the RAI group for whole parameters except inflammatory cell infiltration (P < 0.05). Unlike the RAI group which had marked histopathologic damage, the RAI + NAC group had only mild histologic activity index scores with no granuloma formation observed. Oxidative stress parameters were demonstrated that the NAC treatment significantly decreased the tissue malondialdehyde (MDA) and catalase levels and increased the total sulfhydryl (total sulfhydryl) levels when compared to the RAI group (P < 0.01). Conclusion The outcomes of the study exhibited that the NAC treatment improved RAI-induced early liver damage. This improving effect considered to be caused by its antioxidant, anti-inflammatory, and likely vasodilator properties of NAC. Having advantages such as inexpensive, easy access, and tolerability, the NAC can be used as a radioprotective agent, especially in patients with liver diseases and requiring RAI treatment.

show abstract

Melatonin: a hepatoprotective agent against radioiodine toxicity in rats

Abstract: The results of this study demonstrated that melatonin reduced the harmful effects of RAI treatment on the liver. Anti-inflammatory and antioxidant activities are likely to be involved in the mechanism underlying the radio-protective effects of melatonin (Tab. 3, Fig. 1, Ref. 30).

Cited by 12 publications

References 22 publications

Advanced oxidation protein products play critical roles in liver diseases

Advanced oxidation protein products play critical roles in liver diseases

Melatonin modulate the expression of α1- and β2-adrenoceptors in the hippocampus of rats subjected to unpredictable chronic mild stress

Ameliorating effects of N-acetyl cysteine against early liver damage of radioiodine in rats

Contact Info

Product

Resources

About